

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	1
STUDY GOALS AND OBJECTIVES	1
REASONS FOR DOING THIS STUDY	1
INTENDED AUDIENCE	2
SCOPE OF REPORT	2
METHODOLOGY	2
INFORMATION SOURCES	2
ANALYST CREDENTIALS	3
RELATED BCC REPORTS	3
BCC ONLINE SERVICES	3
DISCLAIMER	3
CHAPTER 2 SUMMARY	5
<i>SUMMARY TABLE GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL THERAPEUTICS BY GEOGRAPHIC REGION, THROUGH 2016 (\$ MILLIONS)</i>	5
<i>SUMMARY FIGURE GLOBAL SALES OF HUMAN ANTIFUNGALS, 2011 AND 2016 (\$ MILLIONS)</i>	6
CHAPTER 3 OVERVIEW	8
HISTORY AND CURRENT STATE OF ANTIFUNGALS	8
TYPES OF PATHOGENIC FUNGI	9
DEFINITION OF THE INDUSTRY	9
CONCEPTS IN THE INDUSTRY	9
IMPORTANCE OF THE INDUSTRY	10
PRODUCT LIFE CYCLES	11
<i>TABLE 1 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG</i>	12
DEVELOPMENT OF ANTIFUNGALS	12
FDA-APPROVED ANTIFUNGALS	13
AZOLE ANTIFUNGALS	13
ECHINOCANDINS	13
POLYENES	13
ALLYLAMINES	13
MISCELLANEOUS ANTIFUNGALS	14
FUTURE DEVELOPMENTS	14
HUMAN CLINICAL DEVELOPMENT, 2009 TO 2011	14
NEW DRUG ACTIVITY	15
<i>TABLE 2 CLINICAL TRIALS OF ALL NEW DRUG THERAPIES AND COMBINATIONS BY ALL DATE FIELDS, 2009-2011</i>	16
<i>TABLE 3 SELECTED GLOBAL CLINICAL TRIALS OF ALL NEW DRUG THERAPIES THAT EITHER ARE COMPLETED OR ESTIMATED TO BE COMPLETED BETWEEN 2009 AND 2012</i>	16
ACTIVE OR COMPLETED STUDIES POSTED OR UPDATED, 2009 TO 2011	16
<i>TABLE 4 ACTIVE OR COMPLETED STUDIES, 2009-2011</i>	16
CHAPTER 4 INTRODUCTION TO INDUSTRY APPLICATIONS OF ANTIFUNGAL MEDICINAL THERAPEUTICS	20
SCOPE OF APPLICATIONS: HUMAN HEALTHCARE	20
HUMAN FUNGAL INFECTIONS	21

TOPIC	PAGE NO.
RISK FACTORS FOR DEVELOPING FUNGAL INFECTIONS	22
<i>TABLE 5 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS</i>	23
FUNGAL SPECIES THAT CAUSE INFECTION IN HUMANS	24
Candidiasis	24
Cutaneous Candidiasis	26
Chronic Mucocutaneous Candidiasis	26
GI Tract Candidiasis	27
Respiratory Tract Candidiasis	27
Genitourinary Tract Candidiasis	27
Hepatosplenic Candidiasis	27
Systemic Candidiasis	27
Candidemia	28
Disseminated Candidiasis	28
Aspergillosis	29
Blastomycosis	30
Coccidioidomycosis	30
Cryptococcosis	31
Dermatophytosis	32
Histoplasmosis	33
Onychomycosis	34
Paracoccidioidomycosis	35
Pseudallescheriasis	35
Sporotrichosis	36
Zygomycosis	36
<i>TABLE 6 INCIDENCE OF COMMON FUNGAL DISEASES</i>	38
MORE RARE FUNGAL INFECTIONS AND DISORDERS	38
Literature Review	39
FUNGAL DRUG RESISTANCE	40
CURRENT DRUG RESISTANCE TOPICS: A GLOBAL VIEW	40
MDR SPECIES	41
Literature Review	43
<i>TABLE 7 COMMON REASONS FOR FUNGAL RESISTANCE</i>	44
STRATEGIES TO IMPROVE RESPONSE AND DECREASE MORTALITY	44
Literature Review	45
CHAPTER 5 HUMAN ANTIFUNGAL AGENTS	47
<i>TABLE 8 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL CONSUMPTION BY PRODUCT TYPE, THROUGH 2016 (\$ MILLIONS)</i>	47
CLASSES OF ANTIFUNGALS	47
ECHINOCANDINS	47
Literature Review	48
AZOLES	48
Literature Review	49
POLYENES	49
Literature Review	49
OTHER	49
<i>TABLE 9 GLOBAL ANTIFUNGAL PHARMACEUTICAL SALES: TRIAZOLES AND ECHINOCANDINS VERSUS OTHER ANTIFUNGALS THROUGH 2016 (\$ MILLIONS)</i>	50

TOPIC	PAGE NO.
<i>TABLE 10 PHARMACEUTICAL ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)</i>	50
<i>FIGURE 1 PERCENTAGE OF RECOGNIZED ANTIFUNGAL DRUGS (%)</i>	50
<i>TABLE 11 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE SALES PRICE PER DOSAGE, 2009</i>	52
<i>TABLE 12 FUNGAL INFECTION AND TRADITIONAL PHARMACEUTICAL REMEDY</i>	53
<i>TABLE 13 TYPE OF CANDIDAL INFECTION AND PHARMACEUTICAL TREATMENT</i>	54
SIDE EFFECTS	54
<i>TABLE 14 LIFE-THREATENING SIDE EFFECTS FROM ANTIFUNGAL PHARMACEUTICALS</i>	56
OTC ANTIFUNGAL PREPARATIONS	56
<i>TABLE 15 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF ADMINISTRATION</i>	58
NATURAL ANTIFUNGAL REMEDIES	58
TYPES OF NATURAL ANTIFUNGAL REMEDIES	59
Herbal Remedies	59
Enzyme-based Antifungal Agents	60
<i>TABLE 16 COMMON NATURAL ANTIFUNGALS</i>	61
SUMMARY OF SELECTED NATURAL ANTIFUNGALS	62
Aloe	62
Literature Review	63
Curcumin	63
Literature Review	64
Mint	64
Literature Review	64
Wild Marjoram	65
Literature Review	65
Radish	65
Literature Review	66
Parnafungins	66
Literature Review	67
Ginseng	67
Literature Review	68
Walnut	68
Literature Review	68
Pau d'arco	68
Literature Review	69
Garlic	69
Literature Review	69
Grapefruit Seed	70
Literature Review	70
Olive Leaf	70
Literature Review	70
Goldenseal	71
Literature Review	71
Oregano	71
Literature Review	71
Tea Tree	72
Literature Review	72
NATURAL REMEDIES IN EARLIER DEVELOPMENT	72
Literature Review	72

TOPIC	PAGE NO.
LABORATORY TESTING AND HISTOPATHOLOGY FOR FUNGAL INFECTIONS IN HUMANS	74
Specimen Examination	74
Cultures	75
Blood Serology	75
ALTERNATIVE HEALTHCARE APPROACHES TO TESTING AND DIAGNOSIS OF FUNGAL INFECTIONS	75
CAM Testing and Specialized Laboratories	75
Questionnaire for Symptoms	76
CHAPTER 6 COMMON ENVIRONMENTAL FUNGI	78
MOLDS AND THE HUMAN ISSUES THEY PRODUCE	78
WHY ENVIRONMENTAL MOLD IS A UNIQUE PROBLEM	79
HEALTH RISKS DUE TO ENVIRONMENTAL FUNGI AND MOLD	80
TABLE 17 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOLDS	81
TABLE 18 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL MOLD REACTIONS	81
TABLE 19 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOLDS	82
ENVIRONMENTAL MOLDS	82
ALTERNARIA	82
Literature Review	83
ASPERGILLUS	83
Literature Review	84
CLADOSPORIUM	84
Literature Review	85
PENICILLIUM	85
Literature Review	86
EUROTIUM	87
Literature Review	87
RHIZOPUS	87
Literature Review	87
MUCOR	88
Literature Review	88
GEOTRICHUM	88
Literature Review	88
FUSARIUM	89
Literature Review	89
STACHYBOTRYS	90
Literature Review	90
WALLEMIA	90
Literature Review	90
TRICHOTHECIUM	91
Literature Review	91
SCOPULARIOPSIS BREVICAILIS	91
Literature Review	91
SCYTALIDIUM DIMIDIATUM	92
Literature Review	92
TRICHODERMA	92
Literature Review	93

TOPIC	PAGE NO.
PAECILOMYCES VARIOTII	93
Literature Review	93
CHAPTER 7 GOVERNMENT REGULATORY AGENCIES AND PROFESSIONAL ASSOCIATIONS	96
GOVERNMENT REGULATIONS	96
FDA	96
<i>TABLE 20 ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA TO MANUFACTURERS, 1997-2011</i>	97
EPA	102
USDA	103
FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS	104
PROFESSIONAL ASSOCIATIONS	104
MEDICAL AND VETERINARY ASSOCIATIONS	104
AGRICULTURAL ASSOCIATIONS	104
OTHER ENVIRONMENTAL ASSOCIATIONS	104
CHAPTER 8 ANTIFUNGAL COMPANIES	107
HUMAN HEALTHCARE	107
PHARMACEUTICAL MANUFACTURERS	107
<i>TABLE 21 MAJOR GLOBAL MANUFACTURERS OF HUMAN ANTIFUNGAL PHARMACEUTICALS</i>	107
<i>FIGURE 2 GLOBAL ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS BY COUNTRY (%)</i>	107
MAJOR PHARMACEUTICAL MANUFACTURER PROFILES	108
<i>TABLE 22 COMPETITIVE MARKET SHARE BY PERCENT, 2011 (%)</i>	109
<i>FIGURE 3 COMPETITIVE MARKET SHARE BY PERCENT, 2011 (%)</i>	109
Astellas Pharma, Inc.	109
Bayer HealthCare	110
Enzon Pharmaceuticals	110
Galderma Pharma SA/Galderma SA	110
Gilead Sciences, Inc.	111
Medicis Pharmaceutical Corp.	111
Novartis International AG	111
Pfizer, Inc.	112
Taro Pharmaceutical Industries, Ltd.	112
Teva Pharmaceutical Industries, Ltd.	112
OTC ANTIFUNGAL MANUFACTURERS	113
PHARMACEUTICAL OTC MARKET	113
<i>TABLE 23 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS</i>	113
MAJOR PHARMACEUTICAL-BASED OTC MANUFACTURER PROFILES	114
Alva-Amco Pharmacal	114
Blaine Labs	114
Dartmouth Pharmaceuticals	115
Del Laboratories	115
Ganeden Biotech	115
Kramer Laboratories	115
Novartis International AG	116
Ortho McNeil	116
PEDiNOL Pharmacal, Inc.	116
Stiefel Laboratories	116

TOPIC	PAGE NO.
Tarmac Products	117
ALTERNATIVE OTC MANUFACTURERS	117
<i>TABLE 24 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS</i>	117
MAJOR ALTERNATIVE OTC MANUFACTURER PROFILES	118
AquaFlora	118
Crystal Star Herbal Nutrition	118
Enzymedica	118
Forest Herbs Research	119
Garden of Life	119
Michael's Naturopathic Programs	119
Nature's Plus	120
NOW Foods	120
Nutrition Now	120
PROSymbiotics	121
Pure Essence Laboratories	121
Rainbow Light	121
Renew Life	122
Solaray	122
Vitanica	122
CHAPTER 9 ANTIFUNGAL INDUSTRY	124
ANTIFUNGAL MARKET TRENDS: HUMAN HEALTHCARE	124
ACCELERATING ANTIFUNGAL DRUG DEVELOPMENT	124
<i>TABLE 25 NEW PRESCRIPTION ANTIFUNGALS, 2005-JANUARY 2012</i>	125
INCREASED TYPES OF TESTING	125
Need to Increase Use and Acceptance of Newer Drugs	126
EXPERIMENTAL RESEARCH: CLINICAL TRIALS PERFORMED AND SELECTED PRECLINICAL AND IN VIVO STUDIES	126
A GENERAL OVERVIEW OF NON-PHARMACEUTICAL ANTIFUNGAL TECHNOLOGIES	127
Laser and Photodynamic Therapy	127
Studies	128
Literature Review	128
mAbs	128
Diagnostics and Assays	129
Literature Review	129
Computer Modeling Technology	130
Literature Review	130
R&D SECTION: AN OVERVIEW OF PRODUCTS IN DEVELOPMENT	130
<i>TABLE 26 ANTIFUNGALS IN DEVELOPMENT</i>	131
TRENDS IN CLASS USED AND ADMINISTRATION METHOD	132
<i>TABLE 27 PHARMACEUTICAL ANTIFUNGALS BY ROUTE OF ADMINISTRATION, 2011 (%)</i>	133
<i>FIGURE 4 PHARMACEUTICAL ANTIFUNGALS BY ROUTE OF ADMINISTRATION, 2011 (%)</i>	133
<i>TABLE 28 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PHARMACEUTICAL PRODUCTS BY ROUTE OF ADMINISTRATION, THROUGH 2016 (\$ MILLIONS)</i>	133
UTILIZATION OF OTC AND NATURAL/ALTERNATIVE ANTIFUNGAL AGENTS	134
Shifting Market From Prescription to OTC	134
Market Demand for OTC Products	134

TOPIC	PAGE NO.
CHAPTER 10 PATENT ANALYSIS	136
PURPOSE OF A PATENT ANALYSIS	136
DUE CARE IN REVIEWING THE PATENT ANALYSIS	136
NEW ANTIFUNGAL PATENTS ISSUED	136
<i>TABLE 29 U.S. ANTIFUNGAL PATENT TRENDS, 1990-2009 (NUMBER OF PATENTS ISSUED)</i>	137
<i>TABLE 30 NEW U.S. ANTIFUNGAL PATENTS ISSUED, 2007-2012</i>	137
<i>TABLE 31 ASSIGNEES OF TWO OR MORE U.S. PATENTS FOR ANTIFUNGAL PRODUCTS, 2007-2011</i>	140
<i>TABLE 32 U.S. PATENT TRENDS BY COUNTRY, 2007-2011 (QUANTITY/%)</i>	140
<i>FIGURE 5 U.S. PATENT TRENDS BY COUNTRY, 2007-2011 (%)</i>	141
TRENDS IN PATENT APPLICATIONS	141
<i>TABLE 33 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007-2011</i>	142
<i>FIGURE 6 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007 THROUGH 2011 (%)</i>	142
<i>TABLE 34 NEW U.S. PATENT APPLICATIONS, 2007-2011</i>	143
<i>TABLE 35 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MECHANISM OF ACTION, 2007-2011</i>	149
<i>TABLE 36 U.S. PATENT APPLICATION TRENDS BY COUNTRY, 2007-2011</i>	149
<i>FIGURE 7 U.S. ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY 2007-2011 (%)</i>	149
PATENT EXPIRATIONS	150
<i>TABLE 37 PATENT EXPIRATIONS 2006-2018</i>	150
CHAPTER 11 APPENDIX	153
<i>TABLE 38 PHARMACEUTICAL COMPANIES</i>	153

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL THERAPEUTICS BY GEOGRAPHIC REGION, THROUGH 2016 (\$ MILLIONS)	5
TABLE 1 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG	12
TABLE 2 CLINICAL TRIALS OF ALL NEW DRUG THERAPIES AND COMBINATIONS BY ALL DATE FIELDS, 2009-2011	16
TABLE 3 SELECTED GLOBAL CLINICAL TRIALS OF ALL NEW DRUG THERAPIES THAT EITHER ARE COMPLETED OR ESTIMATED TO BE COMPLETED BETWEEN 2009 AND 2012	16
TABLE 4 ACTIVE OR COMPLETED STUDIES, 2009-2011	16
TABLE 5 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS	23
TABLE 6 INCIDENCE OF COMMON FUNGAL DISEASES	38
TABLE 7 COMMON REASONS FOR FUNGAL RESISTANCE	44
TABLE 8 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL CONSUMPTION BY PRODUCT TYPE, THROUGH 2016 (\$ MILLIONS)	47
TABLE 9 GLOBAL ANTIFUNGAL PHARMACEUTICAL SALES: TRIAZOLES AND ECHINOCANDINS VERSUS OTHER ANTIFUNGALS THROUGH 2016 (\$ MILLIONS)	50
TABLE 10 PHARMACEUTICAL ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)	50
TABLE 11 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE SALES PRICE PER DOSAGE, 2009	52
TABLE 12 FUNGAL INFECTION AND TRADITIONAL PHARMACEUTICAL REMEDY	53
TABLE 13 TYPE OF CANDIDAL INFECTION AND PHARMACEUTICAL TREATMENT	54
TABLE 14 LIFE-THREATENING SIDE EFFECTS FROM ANTIFUNGAL PHARMACEUTICALS	56
TABLE 15 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF ADMINISTRATION	58
TABLE 16 COMMON NATURAL ANTIFUNGALS	61
TABLE 17 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOLDS	81
TABLE 18 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL MOLD REACTIONS	81
TABLE 19 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOLDS	82
TABLE 20 ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA TO MANUFACTURERS, 1997-2011	97
TABLE 21 MAJOR GLOBAL MANUFACTURERS OF HUMAN ANTIFUNGAL PHARMACEUTICALS	107
TABLE 22 COMPETITIVE MARKET SHARE BY PERCENT, 2011 (%)	109
TABLE 23 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS	113
TABLE 24 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS	117
TABLE 25 NEW PRESCRIPTION ANTIFUNGALS, 2005-JANUARY 2012	125
TABLE 26 ANTIFUNGALS IN DEVELOPMENT	131
TABLE 27 PHARMACEUTICAL ANTIFUNGALS BY ROUTE OF ADMINISTRATION, 2011 (%)	133
TABLE 28 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PHARMACEUTICAL PRODUCTS BY ROUTE OF ADMINISTRATION, THROUGH 2016 (\$ MILLIONS)	133
TABLE 29 U.S. ANTIFUNGAL PATENT TRENDS, 1990-2009 (NUMBER OF PATENTS ISSUED)	137
TABLE 30 NEW U.S. ANTIFUNGAL PATENTS ISSUED, 2007-2012	137
TABLE 31 ASSIGNEES OF TWO OR MORE U.S. PATENTS FOR ANTIFUNGAL PRODUCTS, 2007-2011	140
TABLE 32 U.S. PATENT TRENDS BY COUNTRY, 2007-2011 (QUANTITY/%)	140
TABLE 33 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007-2011	142
TABLE 34 NEW U.S. PATENT APPLICATIONS, 2007-2011	143
TABLE 35 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MECHANISM OF ACTION, 2007-2011	149
TABLE 36 U.S. PATENT APPLICATION TRENDS BY COUNTRY, 2007-2011	149
TABLE 37 PATENT EXPIRATIONS 2006-2018	150

TABLE HEADING	PAGE NO.
TABLE 38 PHARMACEUTICAL COMPANIES	153

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL SALES OF HUMAN ANTIFUNGALS, 2011 AND 2016 (\$ MILLIONS)	6
FIGURE 1 PERCENTAGE OF RECOGNIZED ANTIFUNGAL DRUGS (%)	50
FIGURE 2 GLOBAL ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS BY COUNTRY (%)	107
FIGURE 3 COMPETITIVE MARKET SHARE BY PERCENT, 2011 (%)	109
FIGURE 4 PHARMACEUTICAL ANTIFUNGALS BY ROUTE OF ADMINISTRATION, 2011 (%)	133
FIGURE 5 U.S. PATENT TRENDS BY COUNTRY, 2007-2011 (%)	141
FIGURE 6 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007 THROUGH 2011 (%)	142
FIGURE 7 U.S. ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY 2007-2011 (%)	149